{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:00:17Z","timestamp":1770822017881,"version":"3.50.1"},"reference-count":21,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,3,2]],"date-time":"2007-03-02T00:00:00Z","timestamp":1172793600000},"content-version":"vor","delay-in-days":6391,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[1989,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To extend the clinical\u2010pathologic description of small cleaved cell lymphoma (SCCL), we reviewed the records of 106 patients with SCCL who were treated in accordance with a policy of watchful waiting and palliative therapy. Median age was 58 years. A pure diffuse pattern was seen in only 16 per cent of cases. Stage III or IV disease was present in 85 per cent of patients; marrow involvement was noted in 60 per cent of patients. \u2018B\u2019 symptoms were present in 25 per cent of patients.<\/jats:p><jats:p>By univariate analysis, age &gt; 60, diffuse pattern, stage IV disease, involvement of liver, lung, pleura, or g\u20101 tract, \u2018B\u2019 symptoms, surface heavy chain IgM or IgM\u2010D, and LDH &gt; 200 IU\/dl were found to be significantly associated with a poor prognosis. Marrow involvement, increased (5\u201325 per cent) transformed (non\u2010cleaved) cells, and surface light chain had no prognostic significance.<\/jats:p><jats:p>By multivariate analysis, only age &gt;60, stage IV disease, and LDH &gt; 200 IU\/dl were prognostically significant. For patients with all three unfavourable prognostic features, median survival was only 11 months. For patients with age \u00b1 60, stage I, II, or III disease, and LDH \u00b1 200 IU\/dl, median survival was not reached at 180 months. Recognition of prognostic features in indolent lymphoma can help clarify whether the results of treatment protocols represent true advances or the mere selection of favourable patients.<\/jats:p>","DOI":"10.1002\/hon.2900070506","type":"journal-article","created":{"date-parts":[[2007,2,19]],"date-time":"2007-02-19T20:05:05Z","timestamp":1171915505000},"page":"381-391","source":"Crossref","is-referenced-by-count":3,"title":["Malignant lymphomas of follicular centre cell origin in man. VII. Prognostic features in small cleaved cell lymphoma"],"prefix":"10.1002","volume":"7","author":[{"given":"Richard S.","family":"Stein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Greer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John B.","family":"Cousar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory W.","family":"Hendey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H.","family":"Wehner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Flexner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert D.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,3,2]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197807)42:1<88::AID-CNCR2820420115>3.0.CO;2-U"},{"key":"e_1_2_1_3_1","first-page":"963","article-title":"Prognostic significance of lymphocytic surface markers and histology in adult non\u2010Hodgkin's lymphoma","volume":"61","author":"Bloomfield C. D.","year":"1977","journal-title":"Cancer Treat. Rept."},{"key":"e_1_2_1_4_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox D. R.","year":"1972","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810501)47:9<2247::AID-CNCR2820470924>3.0.CO;2-2"},{"key":"e_1_2_1_6_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood.V58.1.45.45","article-title":"Factors predicting long\u2010term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma","volume":"58","author":"Fisher R. I.","year":"1981","journal-title":"Blood"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820301)49:5<888::AID-CNCR2820490512>3.0.CO;2-K"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/52.1-2.203"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198602000-00011"},{"key":"e_1_2_1_10_1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/blood.V33.2.370.370","article-title":"Combination chemotherapy in lymphosarcoma and reticulum cell sarcoma","volume":"33","author":"Hoogstraten B.","year":"1969","journal-title":"Blood"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197410)34:8 <1488::AID-CNCR2820340822>3.0.CO;2-C"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.6.867"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197608)38:2<964::AID-CNCR2820380248>3.0.CO;2-V"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19831215)52:12<2300::AID-CNCR2820521224>3.0.CO;2-Y"},{"key":"e_1_2_1_17_1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1182\/blood.V47.5.747.747","article-title":"Treatment of advanced non\u2010Hodgkin's lymphomas with favourable histologies: Preliminary results of a prospective trial","volume":"47","author":"Portlock C. S.","year":"1976","journal-title":"Blood"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-104-6-757"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197602)37:2<629::AID-CNCR2820370204>3.0.CO;2-K"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197912)44:6<2236::AID-CNCR2820440635>3.0.CO;2-E"},{"key":"e_1_2_1_21_1","first-page":"224","article-title":"Correlations between immunologic markers and histopathologic classifications: Clinical implications","volume":"7","author":"Stein R. S.","year":"1980","journal-title":"Semin. Oncol."},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197709)40:3<1229::AID-CNCR2820400337>3.0.CO;2-F"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2900070506","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2900070506","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T22:03:53Z","timestamp":1736805833000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2900070506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989,9]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1989,9]]}},"alternative-id":["10.1002\/hon.2900070506"],"URL":"https:\/\/doi.org\/10.1002\/hon.2900070506","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[1989,9]]}}}